Biotechnology

CAR T Cell Therapy Boosted by Biomimetic Platform in Re...

CD71, a protein involved in iron transport, is highly expressed across leukemia ...

The hidden layer of PBMs: What a recent investigation r...

With health care affordability a top concern for many Americans, pharmacy benefi...

AgBio: Redesigning Tomorrow’s Crops

As climate pressure mounts, new platforms tackle delivery, regulation, trait sta...

Pharma’s AI Investment Signals New Drug Discovery Paradigm

Therapeutic developers are increasingly rebuilding their workflows around AI to ...

Simulating Life: 4D Whole-Cell Model of a Minimal Bacte...

A 4D whole-cell simulation of the minimal bacterium JCVI-syn3A models DNA replic...

Sartorius Introduces Rationally-Designed CHO Host Cell ...

The cell line is designed for reliability, with more than 90 percent of evaluate...

Smarter Filings, Smarter Factories

AI is no longer a futuristic add-on in the life sciences. It is rapidly becoming...

Expanding the Druggable Proteome with Tech Advances

We spoke with four leading experts to explore additional therapeutic modalities ...

Top 10 Takeover Targets of 2026

Despite Merck’s comfort with M&A in the “tens of billions” of dollars, the year’...

In Vivo CAR T Therapy Will the Bets Pay Off?

With clinical data beginning to emerge, big pharma is signaling its belief that ...

Genome Editing for Biopharmaceutical Manufacturing

Chinese Hamster Ovary (CHO) cells have been the industrial workhorse for product...

A Noble Pursuit: A Long-Time AI-in-Biotech Skeptic Take...

It is time we talked about artificial intelligence (AI). I have always been a bi...

Fully Continuous Bioprocessing Drops mAb Costs

Continuous biopharmaceutical manufacturing is expected to grow as much as 17% be...

Standouts among Non-CHO Cell Expression Systems

Non-CHO cell expression systems gain traction as faster, more flexible alternati...

GLP-1 Drugs Modulate Gene Expression via MED14 Phosphor...

Salk Institute researchers have uncovered how GLP-1 drugs promote viability and ...

StockWatch: Under Fire from FDA, uniQure Stock Roller-C...

uniQure shares finished the regular trading week down only 9% despite the FDA’s ...